• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Esaote’s E-Scan gets final FDA nod

Article

The Food and Drug Administration last month cleared—for the second time—Italian biomedical firm Esaote’s E-Scan MRI system. Although the agency originally approved the system last summer, the FDA requested another application when

The Food and Drug Administration last month cleared—for the second time—Italian biomedical firm Esaote’s E-Scan MRI system. Although the agency originally approved the system last summer, the FDA requested another application when Genoa-based Esaote made what the FDA considered significant changes in the unit’s gradient system during the final development stage.

E-Scan is an open-style MRI scanner dedicated to orthopedic studies, and includes a swiveling patient table between 0.2-tesla permanent magnets. Esaote supplies the unit to U.S. marketing partners Lunar of Madison, WI, and Siemens Medical Systems of Iselin, NJ (SCAN Special Report 1/99).

The agency’s request for a second 510(k) application for E-Scan came as a surprise, according to Lunar, and delayed the product’s launch. Esaote had planned to ship the units in the first quarter of 1999, but since the second 510(k) application was submitted on March 23 and cleared on May 27, the company’s commercialization calendar was interrupted. Although a Lunar spokesperson downplayed the effect of the delay, Lunar’s third quarter fiscal 1999 (end-March) results took a hit when the company couldn’t recognize revenue for $2.7 million in E-Scan orders (SCAN 4/28/99).

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.